Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
Search
Our Partners: ViraTherapeutics
Our Partners: ViraTherapeutics
Boehringer Ingelheim Cares Product Donations Program
Boehringer Ingelheim Cares Product Donations Program
BI Cares Financial Contributions Program
BI Cares Financial Contributions Program
Welcome to the Neuroscience Gallery | Boehringer Ingelheim US
Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.
Why today’s depression trials demand smart new approaches
Why today’s depression trials demand smart new approaches
A future without pills – could AI change the way we treat psychiatric diseases?
Dr Cornelia Dorner-Ciossek talks about how her work with smartphone tech could transform how we treat mental illness.
Our Environment
Our Environment
A Moment To Reflect on the Evolving Approach for Diabetes Management | Boehringer Ingelheim US
A Moment To Reflect on the Evolving Approach for Diabetes Management
Expanded Access Programs
Expanded Access Programs
Ordering your medicine online? Find a safe pharmacy first.
Learn what to look for when buying medication and how to verify your pharmacy.
What can the Patient do?
What can the Patient do?
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
Sunshine Act Compliance
Sunshine Act Compliance
Standing together in support of improved access to obesity care
Learn more about how we’re supporting The Obesity Society and their recent consensus statement on obesity to help raise awareness and improve access to care for people living with this chronic medical condition.
Let’s find CKD
More than 35 million Americas are living with chronic kidney disease (CKD), and most of them don’t know it. Early diagnosis of CKD needs to be a national priority.
The Urgency for Heart Failure Research and New Treatment Options
The Urgency for Heart Failure Research and New Treatment Options
Boehringer Ingelheim Applauds the Governor's Prevention Partnership for Protecting Connecticut Youth from Drugs and Alcohol for 35 Years
Recently, our colleagues joined Governor Ned Lamont, and his Connecticut's Governor's Prevention Partnership organization to celebrate its 35th anniversary and reaffirm our collective commitment to keeping Connecticut youth safe and substance-free.
Our Purpose
Why we exist
Boehringer Shows Support for Children with Skin Conditions
This year, Boehringer Ingelheim joined campers at Camp Discovery in Millville, PA to demonstrate its support for those facing chronic skin conditions.
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Expert insights: top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
Update on LUME-Meso Clinical Trial
Click here to read an update on the LUME-Meso clinical trial, comparing nintedanib with other treatment options for malignant pleural mesothelioma.